ALSA Ventures
Venture capitalInactiveLondon · Seed–Series A · 13 people tracked
This fund appears to be inactive.
UK Companies House records show ALSA VENTURES LIMITED (no. 09897892) as dissolved. It is unlikely to be making new investments — this profile is kept for reference and historical accuracy.
Find your way into ALSA Ventures
1,490 people in our graph share verified history with the ALSA Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
ALSA Ventures backs biotechnology companies developing novel therapies for patients, with a primary focus on therapeutics. The firm seeks novel drugs and modalities across a broad range of disease areas and invests along the full spectrum of drug development. It supports companies from spinoff through to public market listing and is comfortable both leading company formation and participating in syndicates alongside co-investors. ALSA believes European life sciences innovation can create valuable businesses with global impact, and the combination of that innovation with the European investment market opportunity underpins the firm's Europe-focused strategy.
Source: firm website, verified Aug 3, 2026.
Team · 13 people
from the firm's website & public directories
Founder mafia
4 people who came through ALSA Ventures went on to found or lead other companies.
What they invest in
from 11 of 12 portfolio companiesBiotech ×9Healthtech ×8Deep Tech ×3Medical Devices ×3SaaS ×2AI & Machine Learning ×1B2B Marketplaces ×1Consumer ×1
HQs:United Kingdom×3Belgium×2Bangladesh×1Switzerland×1
Investments · 12 tracked
founders shown can be your intro pathBy year:2023 · 12015 · 23 dated
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIBPfizer Venture InvestmentsPolaris Partners
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIBPfizer Venture Investments
Axovia Therapeutics develops AAV9-based gene therapies for ciliopathies, a group of rare inherited genetic diseases, with a lead program targeting Bardet-Biedl Syndrome (BBS1) to prevent blindness and reverse obesity.
BiotechDeep TechHealthtech
Phil Beales(Co-founder)inVictor Hernandez(Co-founder & Chief Scientific Officer)in
Co-investorsAlbionVC
Mailchimp is an email and SMS marketing platform that helps businesses of all sizes automate customer communications and drive revenue through AI-powered analytics and campaign tools.
E-commerceMarketing TechSaaS
Co-investors24 HaymarketDecisive PointFifth WallFitz Gate VenturesForma PrimeHello Tomorrow+10 more
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investors3B Future Health FundAlbionVCEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology Fund+1 more
Jatri is a global B2B travel commerce platform that digitizes transport operators and travel buyers through a unified technology and finance ecosystem.
B2B MarketplacesConsumerLogistics & Supply ChainMobility & TransportationSaaSTravel & HospitalityDhaka, BD
Aziz Arman(Founder & CEO)in
Co-investorsDoha Tech AngelsGobi PartnersLoftyInc CapitalReflect VenturesSprint VcBrain-Too-Free Ventures+3 more
Oxford BioTherapeutics is a clinical-stage oncology company developing antibody-based therapies for cancer treatment.
BiotechHealthtechMedical DevicesOxford, GB
Co-investorsCalculus Capital Ltd.OxfordPercipient CapitalPerscitus LLP
Presage Biosciences is a translational oncology company that operates the CIVO (Comparative In Vivo Oncology) platform, a patented intratumoral drug delivery and analysis technology for evaluating how tumors respond to multiple investigational treatments.
BiotechDeep TechHealthtech
Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting.
AI & Machine LearningBiotechDeep Tech
BoardGraeme Martin(Executive Chairman)in
ReproNovo develops therapeutic solutions for male and female fertility and women's health conditions like adenomyosis, targeting unmet medical needs in reproductive medicine.
BiotechFemTechHealthtechMedical DevicesLausanne, CH
Co-investorsJeito CapitalM VenturesYsios Capital
Co-investorsAdBio partnersGlobal Health Investment CorporationIn-Q-Tel
Vantage Biosciences develops clinical-stage drug therapies for retinal and other diseases, with a focus on the AOC3 target and its role in liver and eye disease.
BiotechHealthtechMedical Devices
BoardAlek Safarian(Founder)in
Portfolio news
latest coverage across their companiesEepurl · isocfoundation.org · Feb 20, 2026
Montis Biosciences · rupress.org · Jan 5, 2026
Principals & officers · per Companies House
what is this? ⓘDirector · Saudi Arabian · since 2015
Mansour Bin Musllam — 75–100% of shares, 75–100% of voting rights, right to appoint and remove directors
Frequently asked questions
- How many investments has ALSA Ventures made?
- ALSA Ventures has 12 tracked investments.
- What stage does ALSA Ventures invest at?
- ALSA Ventures invests at the Seed, Series A stages.
- What sectors does ALSA Ventures focus on?
- ALSA Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is ALSA Ventures located?
- ALSA Ventures is headquartered in London, GB.
- Who does ALSA Ventures co-invest with?
- ALSA Ventures most often shares deals with AlbionVC, Epidarex Capital, Nauta Capital, among 30 tracked co-investors.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.